APX 701
Alternative Names: APX-701Latest Information Update: 28 Dec 2024
At a glance
- Originator Apexigen
- Developer Pyxis Oncology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; SIRPA protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology
- 14 Apr 2021 Pharmacodynamics data from a preclinical study in Cancer presented at the American Association for Cancer Research (AACR) Annual Meeting 2021 (AACR2021)